Skip to main content

Advertisement

SpringerLink
Log in

Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 15 March 2017

Abstract

Purpose

To investigate the impact of metabolic syndrome (MetS) on benign prostatic hyperplasia (BPH), focusing on MetS and its relationship with prostate volume and prostate-specific antigen (PSA) in Chinese patients by performing a meta-analysis.

Methods

We systematically searched the PubMed, Embase, China National Knowledge Infrastructure, Wanfang, and VIP databases from inception to November 2014. All studies investigating the impact of MetS on prostate volume and PSA among BPH patients were included. Pooled mean difference (WMD) and 95 % confidence interval (CI) were used to analyze the difference between patients with MetS and those without MetS.

Results

Sixteen studies enrolled 1895 BPH patients, of whom 2224 had MetS. Compared with those without MetS, BHP patients with MetS had significantly higher total prostate volume (WMD 10.15 ml; 95 % CI 7.37–12.93) and serum PSA level (WMD 0.53 ng/ml; 95 % CI 0.17–0.88), respectively. In addition, annual prostate growth rate in patients with MetS was higher (WMD 0.49 ml/year; 95 % CI 0.24–0.73) than in those without MetS.

Conclusions

This meta-analysis supports that the presence of MetS increases total prostate volume and annual prostate growth rate in Chinese BPH patients. Future studies are needed to explain the detailed underlying mechanisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Issa MM, Regan TS (2007) Medical therapy for benign prostatic hyperplasia—present and future impact. Am J Manag Care 13(Suppl 1):S4–S9

    PubMed  Google Scholar 

  2. Barry MJ, Fowler Jr FJ, Bin L et al (1997) The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol 157(1):10–14; discussion 14–15

  3. Stroup SP, Palazzi-Churas K, Kopp RP et al (2012) Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008. BJU Int 109(1):84–87

    Article  PubMed  Google Scholar 

  4. Parsons JK (2007) Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol 178(2):395–401

    Article  PubMed  Google Scholar 

  5. De Nunzio C, Aronson W, Freedland SJ et al (2012) The correlation between metabolic syndrome and prostatic diseases. Eur Urol 61(3):560–570

    Article  PubMed  Google Scholar 

  6. Hammarsten J, Hogstedt B, Holthuis N et al (1998) Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1(3):157–162

    Article  CAS  PubMed  Google Scholar 

  7. Grundy SM, Cleeman JI, Daniels SR et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17):2735–2752

    Article  PubMed  Google Scholar 

  8. Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 23(5):469–480

    Article  CAS  PubMed  Google Scholar 

  9. Cooperative Research Group of Diabetic metabolic syndrome of Chinese Medical Association (2004) Proposal of endocrine branch of Chinese medical association. Chin J Diabetes 12(3):156–161

    Google Scholar 

  10. Joint committee for developing Chinese guidelines on prevention and treatment of dyslipidemia in adults (2007) Chinese guidelines on prevention and treatment of dyslipidemia in adults. Chin J Cardiol 35(5):390–416

    Google Scholar 

  11. Wells G, Shea B, O’Connell D et al (2014) The Newcastle–Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 20 Dec 2014

  12. Higgins JPT, Green Se Cochrane handbook for systematic reviews of interventions version 5.0.2. www.cochrane-handbook.org

  13. Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101

    Article  CAS  PubMed  Google Scholar 

  15. Cao B, Sun HB, Su JH et al (2010) Correlation between metabolic syndrome and clinical progression in patients with benign prostatic hyperplasia. Zhonghua Yi Xue Za Zhi 90(40):2823–2825

    CAS  PubMed  Google Scholar 

  16. Chen DX, Chen QQ, Li YB (2010) Clinical characteristics of patients with prostatic hyperplasia combined metabolic syndrome. Chin J Gerontol 30(14):2065–2066

    Google Scholar 

  17. Zhou Y, Zhou SB, Wang W et al (2012) Clinical correlation of benign prostatic hyperplasia and metabolic syndrome in elderly patients. Chin J Gerontol 32(11):4895–4898

    CAS  Google Scholar 

  18. Wei CY, Zhang DD, Lu T (2012) Relationship between benign prostatic hyperplasia and metabolic syndrome in elderly men. J Dalian Med Univ 34(1):75–77

    Google Scholar 

  19. Liu C, Du WH, Zheng TL et al (2012) Relationship between metabolic syndrome and benign prostatic hyperplasia. Prog Mod Biomedici II 29(12):5695–5697

    Google Scholar 

  20. Ding LH (2012) Relationship between metabolic syndrome and prostate volume in BPH under 50 years old. Chin J Endourol (Electron Ed) 6(4):296–300

    Google Scholar 

  21. Wang J, Yang B, Feng YL et al (2012) Relationship between metabolic syndrome and senile prostate hyperplasia. Chin J Diffic Compl Cas 11(10):791–792

    CAS  Google Scholar 

  22. Miao L, Chen Z, Gao CY et al (2013) Influence of metabolic syndrome on aged patients with benign prostatic hyperplasia. J Mod Med Health 29(10):1446–1450

    Google Scholar 

  23. Zhang YW, Yang J (2013) The effect of metabolic syndrome on pathogenesis of benign prostatic hyperplasia. China Mod Dr 51(9):8–10

    Google Scholar 

  24. Zhou XP, Xiong GG, Xu HP et al (2013) Correlation analysis of metabolic syndrome and benign prostatic hyperplasia. China Foreign Med Treat 32(27):54–55

    Google Scholar 

  25. Wang JF, Gai YN, Sun YH (2013) Clinical study of correlation between BPH and metabolic syndrome in elderly. J Clin Urol (China) 28(12):932–934

    CAS  Google Scholar 

  26. Bao JC, Wang HQ, Zuo JQ et al (2013) Study on the relationship metabolic syndrome and prostate volume of annual growth rate. Med Inf 26(1):242–243

    Google Scholar 

  27. Yu CH, Liu ZZ, Su YQ et al (2013) Correlation of metabolic syndrome and prostatic hyperplasia. Tianjin Med J 41(11):1117–1118

    CAS  Google Scholar 

  28. Wang MH, Mo LY, Wu YH (2014) Clinical correlation of benign prostatic hyperplasia and metabolic syndrome in elderly patients. J Clin Med Pract 18(17):149–151

    Google Scholar 

  29. Pan JG, Jiang C, Luo R et al (2014) Association of metabolic syndrome and benign prostatic hyperplasia in Chinese patients of different age decades. Urol Int 93(1):10–16

    CAS  PubMed  Google Scholar 

  30. Zhang X, Zeng X, Liu Y et al (2014) Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men. Urol Int 93(2):214–219

    Article  CAS  PubMed  Google Scholar 

  31. Mochtar CA, Kiemeney LA, van Riemsdijk MM et al (2003) Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 44(6):695–700

    Article  CAS  PubMed  Google Scholar 

  32. Crawford ED, Wilson SS, McConnell JD et al (2006) Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175(4): 1422–1426; discussion 1426–1427

  33. Baillargeon J, Pollock BH, Kristal AR et al (2005) The association of body mass index and prostate-specific antigen in a population-based study. Cancer 103(5):1092–1095

    Article  PubMed  Google Scholar 

  34. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H et al (2007) The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 51(1): 199–203; discussion 204–196

  35. Jeong JH, Kim ET, Kim DK (2011) Association of metabolic syndrome and benign prostate enlargement in young korean males. Korean J Urol 52(11):757–762

    Article  PubMed  PubMed Central  Google Scholar 

  36. Lee YC, Liu CC, Juan YS et al (2013) The impact of metabolic syndrome on the responsiveness to alpha1-blocker in men with BPH/LUTS. Int J Clin Pract 67(4):356–362

    Article  CAS  PubMed  Google Scholar 

  37. Gao Y, Wang M, Zhang H et al (2012) Are metabolic syndrome and its components associated with lower urinary tract symptoms? Results from a Chinese male population survey. Urology 79(1):194–201

    Article  PubMed  Google Scholar 

  38. Park YW, Min SK, Lee JH (2012) Relationship between lower urinary tract symptoms/benign prostatic hyperplasia and metabolic syndrome in Korean men. World J Mens Health 30(3):183–188

    Article  PubMed  PubMed Central  Google Scholar 

  39. Wang Z, Olumi AF (2011) Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia. Differentiation 82(4–5):261–271

    Article  CAS  PubMed  Google Scholar 

  40. Marker PC, Donjacour AA, Dahiya R et al (2003) Hormonal, cellular, and molecular control of prostatic development. Dev Biol 253(2):165–174

    Article  CAS  PubMed  Google Scholar 

  41. Kassi E, Pervanidou P, Kaltsas G et al (2011) Metabolic syndrome: definitions and controversies. BMC Med 9:48

    Article  PubMed  PubMed Central  Google Scholar 

  42. Robert G, Descazeaud A, Nicolaiew N et al (2009) Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 69(16):1774–1780

    Article  PubMed  PubMed Central  Google Scholar 

  43. Sur G, Floca E, Kudor-Szabadi L, Sur ML, Sur D et al (2014) The relevance of inflammatory markers in metabolic syndrome. Maedica (Buchar) 9(1):15–18

    Google Scholar 

  44. Gacci M, Vignozzi L, Sebastianelli A et al (2013) Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis 16(1):101–106

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Molecular Biology and Translational Medicine, the Affiliated People’s Hospital, Jiangsu University, Zhenjiang, 212002, Jiangsu, People’s Republic of China

    Chen Zou, Dandan Gong, Na Fang & Yu Fan

Authors
  1. Chen Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dandan Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Na Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yu Fan.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zou, C., Gong, D., Fang, N. et al. Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients. World J Urol 34, 281–289 (2016). https://doi.org/10.1007/s00345-015-1626-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-015-1626-0

Keywords

Search

Navigation